Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Warned by FDA Over its MASCT Platform

NEW YORK (GenomeWeb News) – Atossa Genetics today disclosed it has been warned by the US Food and Drug Administration over its system for the analysis of nipple aspirate fluid.

In a document filed with the US Securities and Exchange Commission, Atossa said that it received a warning letter from FDA regarding the system called Mammary Aspirate Specimen Cytology Test System, or MASCT, on Feb. 21.

FDA alleges in its warning that after MASCT was cleared by FDA, Atossa made changes to the platform that requires submission of an additional 510(k) notification, Atossa said

"Specifically, the FDA observes that the Instructions For Use (IFU) in the original 510(k) submission stated that the user must 'Wash the collection membrane with fixative solution into the collection vial…' and the current IFU states '…apply one spray of Saccomanno’s Fixative to the collection membrane…' and that 'this change fixes the [nipple aspirate fluid] specimen to the filter paper rather than washing it into a collection vial,'" Atossa said in its SEC document.

It added that when it made the changes to MASCT, it determined that based on FDA's guidance document "Deciding When to Submit a 510(k) for a Change to an Existing Device," not new submission was required.

The warning letter arises from FDA findings during an inspection during the summer. Atossa said that it responded in August to FDA and concerns that it had, providing reasons it believed it was in compliance with "applicable regulations and/or was implementing changes responsive to the findings of the FDA inspection."

Additionally, FDA has told the company that it has certain issues to the way Atossa markets the instrument as well as its compliance with FDA Good Manufacturing Practices regulation, and other matters.

Atossa is cooperating with FDA to resolve the issues, it said, but FDA may require it to submit and receive clearance of a new 10(k0 notice for the current iteration of MASCT, or the company may "revert to marketing the system using prior [nipple aspirate fluid] processing method."

The company has until March 14 to respond the FDA letter.

The MASCT system collects, ships, and analyzes nipple aspirate fluid, which contains cells and biomarkers that may be useful for the detection of breast cancer, as well as cellular changes that may portend breast cancer.

Seattle-based Atossa went public in November.

In afternoon trading on the Nasdaq, shares of Atossa were down 5 percent to $6.59.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.